StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3076% below fair value
$5.01+0.18 (+3.73%)

Close on Nov 18, 2026Market cap $208.38MP/E –Yield –

RxSight revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

RxSight's revenue for the twelve months ending Jun 30, 2026 was $127.58M, down 13.2% year over year. For fiscal 2025 it was $134.48M, down 3.9% from the year before. The highest annual figure on record is $139.93M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$134.48M-3.9%
FY2024Dec 31, 2024$139.93M+57.1%
FY2023Dec 31, 2023$89.08M+81.8%
FY2022Dec 31, 2022$49.01M+116.9%
FY2021Dec 31, 2021$22.59M+53.9%
FY2020Dec 31, 2020$14.68M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.74M+0.3%
Q1 FY2026Mar 31, 2026$30.89M-18.5%
Q4 FY2025Dec 31, 2025$32.61M-18.9%
Q3 FY2025Sep 30, 2025$30.34M-14.1%
Q2 FY2025Jun 30, 2025$33.64M-3.6%
Q1 FY2025Mar 31, 2025$37.90M+28.4%
Q4 FY2024Dec 31, 2024$40.21M+40.7%
Q3 FY2024Sep 30, 2024$35.31M+59.1%
Q2 FY2024Jun 30, 2024$34.89M+67.6%
Q1 FY2024Mar 31, 2024$29.51M+68.7%
Q4 FY2023Dec 31, 2023$28.58M+77.6%
Q3 FY2023Sep 30, 2023$22.20M+76.0%
Q2 FY2023Jun 30, 2023$20.81M+83.2%
Q1 FY2023Mar 31, 2023$17.49M+95.6%
Q4 FY2022Dec 31, 2022$16.09M+90.9%
Q3 FY2022Sep 30, 2022$12.62M+118.0%
Q2 FY2022Jun 30, 2022$11.36M+132.0%
Q1 FY2022Mar 31, 2022$8.94M+156.7%
Q4 FY2021Dec 31, 2021$8.43M+71.5%
Q3 FY2021Sep 30, 2021$5.79M+38.8%
Q2 FY2021Jun 30, 2021$4.90M+81.0%
Q1 FY2021Mar 31, 2021$3.48M–
Q4 FY2020Dec 31, 2020$4.91M–
Q3 FY2020Sep 30, 2020$4.17M–
Q2 FY2020Jun 30, 2020$2.71M–

More RxSight figures

See a number that looks wrong?